Figure 1.
ADCC Induced by Rituximab (Left) and Obinutuzumab (GA-101, Right) in Daudi Cells. 2 hr T and 24 hr C Represent Continuous Pre-Exposure to Ibrutinib (200 nm), While 2hr T/24 hr WO Represents the 2 hr Exposure to Ibrutinib Followed by 24 hr Washout Period